| 注册
首页|期刊导航|山东医药|ARF-BP1基因对肝癌 HepG2细胞凋亡的影响及其机制探讨

ARF-BP1基因对肝癌 HepG2细胞凋亡的影响及其机制探讨

覃新干 罗殿中 吕自力 陈罡 苏传丽

山东医药Issue(32):4-6,3.
山东医药Issue(32):4-6,3.DOI:10.3969/j.issn.1002-266X.2014.32.002

ARF-BP1基因对肝癌 HepG2细胞凋亡的影响及其机制探讨

Effect of ARF-BP1 gene on the apoptosis of HepG2 cells and its mechanism

覃新干 1罗殿中 1吕自力 1陈罡 1苏传丽1

作者信息

  • 1. 广西医科大学第一附属医院,南宁530021
  • 折叠

摘要

Abstract

Objective To investigate the effect of ARF-BP1 gene on apoptosis of hepatoma HepG2 cells, and to ex-plore its mechanism.Methods HepG2 cells in logarithmic growth phase were randomly divided into 4 groups.Transfec-tion group was transfected translently by 100 nmol/L ARF-BP1 siRNA with LipofectamineTM 2000;liposome control group was only added liposomes; negative control group was transfected by negative siRNA fragments; blank control group was added the same amount of medium only, without siRNA fragments and liposomes.The flow cytometry was utilized to detect cells apoptosis rate of 4 groups; RT-PCR was used to detect the relative expression of p53, Mcl-1 mRNA in transfection group and blank control group.Results The apoptosis rate of transfection group, liposome control group, negative control group and blank control group were 27.90%±1.40%, 3.33%±0.66%, 3.05%±0.73% and 1.64%±0.12%, re-spectively;transfection group compared with other groups, all P<0.01; negative control group and liposome group com-pared with the control group, both P<0.05.72 h after transfection, p53, Mcl-1 mRNA relative expression in transfection group were 0.29 ±0.08 and 0.23 ±0.04, significantly lower than those in the blank control group ( P<0.01 and P<0.05).Conclusion Reduced ARF-BP1 gene expression in HepG2 cells can promote tumor cell apoptosis, which maybe correlate with inhibition of p53, Mcl-1 expression.

关键词

肝癌/HepG2细胞/泛素连接酶/ARF-BP1

Key words

hepatoma/HepG2 cell/ubiquitinligating enzyme/ARF-BP1

分类

医药卫生

引用本文复制引用

覃新干,罗殿中,吕自力,陈罡,苏传丽..ARF-BP1基因对肝癌 HepG2细胞凋亡的影响及其机制探讨[J].山东医药,2014,(32):4-6,3.

基金项目

广西自然科学基金资助项目(桂科自0542071);广西科学研究与技术开发计划资助项目(桂科能05112001-4D)。 ()

山东医药

OA北大核心CSTPCD

1002-266X

访问量0
|
下载量0
段落导航相关论文